Giovanni Caforio
CIK 1533201 · Executive Chair of the Board · last filed 2026-05-08
Giovanni Caforio is an Executive Chair of the Board who has filed 61 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for SYK, was dated May 8, 2026. Across all open-market trades the lifetime net is −$46.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $22.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$22.65M
4
61
-$46.80M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYK | Director | 4,530 | $312.20 | $1.41M | $0 | 8 | 2026-05-08 |
| CELGr | Executive Chair of the Board | 400,946 | $0.12 | $49.3K | -$36.21M | 16 | 2024-03-12 |
| BMY | Chairman and CEO | 370,840 | $57.13 | $21.19M | -$6.83M | 25 | 2019-05-06 |
| BRISTOL MYERS SQUIBB CO (BMYp) Delisted | Pres., US Pharmaceuticals | 47,316 | — | — | -$3.76M | 12 | 2013-05-31 |
Recent Filings
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-08 | SYK | Grant (A) | +762 | $0 | EDGAR |
| 2025-05-12 | SYK | Grant (A) | +560 | $0 | EDGAR |
| 2024-05-13 | SYK | Grant (A) | +653 | $0 | EDGAR |
| 2024-03-12 | CELGr | Mixed | +64,771 | -$3.65M | EDGAR |
| 2023-10-12 | CELGr | Gift (G) | −440 | $0 | EDGAR |
| 2023-05-12 | SYK | Grant (A) | +705 | $0 | EDGAR |
| 2023-05-08 | SYK | Exer (M) | +841 | $0 | EDGAR |
| 2023-03-14 | CELGr | Mixed | +131,831 | -$9.07M | EDGAR |
| 2023-02-08 | CELGr | Sell (S) | −240,000 | -$17.92M | EDGAR |
| 2022-09-22 | CELGr | Sell (S) | −25,000 | -$1.74M | EDGAR |